Research indicates that neutralizing IL‐17 and IFNγ can inhibit the migration of BC cell lines (BCCLs), demonstrating their pathogenic roles [48]; conversely, supplementing IL‐17 enhances BCCL migration, with IFNγ further amplifying this effect. This evidence concerns the gene IFNG and breast cancer.